Published in

Elsevier, The Lancet, 10023(387), p. 1066-1074, 2016

DOI: 10.1016/s0140-6736(15)01167-8

Links

Tools

Export citation

Search in Google Scholar

Cediranib in patients with relapsed platinum-sensitive ovarian cancer (ICON6): a randomised, double-blind, placebo-controlled phase 3 trial

Journal article published in 2016 by Jonathan A. Ledermann, Andrew C. Embleton, Fharat Raja, Timothy J. Perren ORCID, Gordon C. Jayson, Gordon J. S. Rustin, Stan B. Kaye, Hal Hirte, Elizabeth Eisenhauer, Michelle Vaughan, Michael Friedlander, Antonio González-Martín, Daniel Stark, Elizabeth Clark, Laura Farrelly and other authors.
This paper was not found in any repository, but could be made available legally by the author.
This paper was not found in any repository, but could be made available legally by the author.

Full text: Unavailable

Green circle
Preprint: archiving allowed
Upload
Green circle
Postprint: archiving allowed
Upload
Red circle
Published version: archiving forbidden
Policy details
Data provided by SHERPA/RoMEO

Abstract

Angiogenesis is a validated clinical target in advanced epithelial ovarian cancer. Cediranib is an oral antiangiogenic vascular endothelial growth factor receptor 1-3 inhibitor that has shown antitumour activity in recurrent ovarian cancer. We assessed efficacy and safety of cediranib in combination with platinum-based chemotherapy and as continued maintenance treatment in patients with first relapse of platinum-sensitive ovarian cancer.